Archive \ Volume.15 2024 Issue 4

Hematological Markers and Coagulation Profiles in COVID-19 Patients: A Retrospective Cohort in Jeddah, Saudi Arabia

Nada Bajuaifer*✉ , Samah Mokhles
  1. Department of Molecular Hematology, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  2. Laboratory of Hematology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.

Abstract

SARS-CoV-2 infection usually results in multi-organ affection, and severe inflammatory response which associated with significant affection of blood cell count and coagulation profile. We aimed to study the changes in haematological parameters among patients infected with SARS-CoV2 and its relation to the severity of infection. A retrospective cohort investigated data from patients hospitalized at the Armed Forces Hospital in Jeddah, Saudi Arabia, between July 2020 and July 2022. Patient who tested positive for SARS-CoV 2 infection were compared to negative patients.

A total of 586 patients were included, 387 tested positive for SARS-CoV-2. COVID-19 patients had significant lower leukocyte, and eosinophil counts along with lower red blood cell indices, suggesting a potential impact on the hematopoietic system. Deviation in leukocyte count was correlated with disease severity. the mortality was higher in the non-COVID-19 group (14.1 vs. 7.5%). COVID-19 patients had significantly higher fibrinogen levels and lower prothrombin time than non-COVID-19 patients. No difference was found regarding liver enzymes, renal function tests or acute-phase reactants. Haematological parameters could be used as markers for early detection, assessment of disease severity, and prognosis of SARS-CoV-2 infection. Further studies are necessary to understand the underlying mechanisms and their clinical significance.


Downloads: 218
Views: 374

How to cite:
Vancouver
Bajuaifer N, Mokhles S. Hematological Markers and Coagulation Profiles in COVID-19 Patients: A Retrospective Cohort in Jeddah, Saudi Arabia. Arch Pharm Pract. 2024;15(4):45-52. https://doi.org/10.51847/Fz5w5tK1gc
APA
Bajuaifer, N., & Mokhles, S. (2024). Hematological Markers and Coagulation Profiles in COVID-19 Patients: A Retrospective Cohort in Jeddah, Saudi Arabia. Archives of Pharmacy Practice, 15(4), 45-52. https://doi.org/10.51847/Fz5w5tK1gc

Download Citation
References
  1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13.
  2. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2.
  3. Alyami MH, Naser A, Alyami H, Alwafi H, Orabi M. Epidemiology of COVID-19 in the kingdom of Saudi Arabia: An ecological study. In: 0601 - Epidemiology [Internet]. European Respiratory Society; 2022. doi:10.1183/13993003.congress-2022.752
  4. Salam AA, Al-Khraif RM, Elsegaey I. COVID-19 in Saudi Arabia: An overview. Front Public Health. 2021;9:736942.
  5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.
  6. Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, et al. Pharmacological agents targeting thromboinflammation in COVID-19: Review and implications for future research. Thromb Haemost. 2020;120(7):1004-24.
  7. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32.
  8. The OpenSAFELY Collaborative, Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, et al. OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients [Internet]. bioRxiv. medRxiv; 2020. doi:10.1101/2020.05.06.20092999
  9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
  10. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81.
  11. Matsushita K, Ding N, Kou M, Hu X, Chen M, Gao Y, et al. The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: A systematic review and meta-analysis. Glob Heart. 2020;15(1):64.
  12. Miller TE, Garcia Beltran WF, Bard AZ, Gogakos T, Anahtar MN, Astudillo MG, et al. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital [Internet]. bioRxiv. medRxiv; 2020. doi:10.1101/2020.06.19.20135723
  13. Arslan Ş, Delice O, Kahraman M, Yilmaz SI, Aslan MH. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in Turkey. Ann Clin Anal Med. 2021;12(05). doi:10.4328/acam.20310
  14. Gajendra S. Spectrum of hematological changes in COVID-19. Am J Blood Res. 2022;12(1):43-53.
  15. Letícia de Oliveira Toledo S, Sousa Nogueira L, das Graças Carvalho M, Romana Alves Rios D, de Barros Pinheiro M. COVID-19: Review and hematologic impact. Clin Chim Acta. 2020;510:170-6.
  16. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020;34(101623):101623.
  17. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722-6.
  18. Qin Y, Xu J, Zhang Z, Wang L, Li J, Jiang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Zhongguo Ke Xue. 2020;50(3):258-69.
  19. Moon AM, Barritt AS. Elevated liver enzymes in patients with COVID-19: Look, but not too hard. Dig Dis Sci. 2021;66(6):1767-9.
  20. Liu Z, Li J, Long W, Zeng W, Gao R, Zeng G, et al. Bilirubin levels as potential indicators of disease severity in Coronavirus disease patients: A retrospective cohort study. Front Med. 2020;7:598870.
  21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
  22. Qian JY, Wang B, Liu BC. Acute kidney injury in the 2019 novel Coronavirus disease. Kidney Dis (Basel). 2020;323(5):1-6.
  23. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020;95(6):E131-4.
  24. Fan BE. Hematologic parameters in patients with COVID-19 infection: A reply. Am J Hematol. Wiley. 2020;95(8):E215.
  25. Ranganadhareddy A, Chandrasekhar C. Applications of biopolymers in bioengineering: A comprehensive review. J Biochem Technol. 2023;14(3):84-7.
  26. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y, et al. Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J Leukoc Biol. 2021;109(1):13-22.
  27. Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88(1):15-27.
  28. Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus. 2020;12(4):e7560.
  29. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
  30. Rosenbaum L. The untold toll-the pandemic’s effects on patients without Covid-19. Mass Medical Soc. 2020;382(24):2368-71.
  31. Hartnett KP, Kite-Powell A, Devies J, Coletta MA, Boehmer TK, Adjemian J. Impact of the COVID-19 pandemic on emergency department visits-United States. Morb Mortal Wkly Rep. 2019;69(23).
  32. Rossen LM, Branum AM, Ahmad FB, Sutton P, Anderson RN. Excess deaths associated with COVID-19, by age and race and ethnicity-United States. Morb Mortal Wkly Rep. 2020;69(42).
  33. Guo Z, Zhang Z, Prajapati M, Li Y. Lymphopenia caused by virus infections and the mechanisms beyond. Viruses. 2021;13(9):1876. doi:10.3390/v13091876
  34. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-41.
  35. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9.
  36. Lippi G, Mattiuzzi C. Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol Transfus Cell Ther. 2020;42(2):116-7.
  37. Elkhalifa AME, Elderdery AY, Al Bataj IA, Tamomh AG, Alyami MM, Almakrami HA, et al. Hematological findings among COVID-19 patients attending King Khalid hospital at Najran, Kingdom of Saudi Arabia. Biomed Res Int. 2022;2022(1):4620037.
  38. Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med. 2021;26(4):415-25.
  39. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: A position paper from Italian society on thrombosis and haemostasis (SISET). Blood Transfus. 2020;18(3):167-9.
  40. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6.
  41. Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:115-24.
  42. Wu MY, Yao L, Wang Y, Zhu XY, Wang XF, Tang PJ, et al. Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir Res. 2020;21(1):171.
  43. Yan L, Zhang HT, Goncalves J, Xiao Y, Wang M, Guo Y, et al. An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell. 2020;2(5):283-8.
  44. Akdogan D, Guzel M, Tosun D, Akpinar O. Diagnostic and early prognostic value of serum CRP and LDH levels in patients with possible COVID-19 at the first admission. J Infect Dev Ctries. 2021;15(6):766-72.
  45. Majidi N, Majidi H. Investigation on the relationship between D-dimer and Cell blood count Indices in COVID-19 prognosis: A retrospective study on 320 COVID-19 patients. J Patient Saf Qual Improv. 2022;10(1):11-8.
  46. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.
  47. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol. 2020;92(10):1733-4.
  48. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Correction: Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):61.
  49. Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev Hematol. 2020;13(11):1265-75.
  50. Muñiz-Diaz E, Llopis J, Parra R, Roig I, Ferrer G, Grifols J, et al. Relationship between the ABO blood group and COVID-19 susceptibility, severity and mortality in two cohorts of patients. Blood Transfus. 2021;19(1):54-63.

 

 

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.